Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers

Correction of Nasolabial Folds Clinical Trial

Official title:

A Randomized, Evaluator-Blind, Bilateral Comparison of an Injection Assistance Device Versus Manual Injections for Delivery of Dermal Fillers in Patients Seeking Aesthetic Correction of the Nasolabial Folds

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01492140
• Other study ID #: NM-11-01
• Status: Unknown status
• Phase: Phase 4
• First received: December 7, 2011
• Last updated: December 12, 2011
• Start date: December 2011
• Est. completion date: February 2012

Study information

• Verified date: December 2011
• Source: TKL Research, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to characterize the safety and performance in normal therapeutic use of the Artiste System in comparison to standard manual administration of dermal fillers. Subjects are recruited from the investigator's practice and randomized to receive treatment with the Artiste System on either the left or right nasolabial fold, the contralateral fold to be treated with standard manual injections. Treatments occur in a single session to achieve optimal cosmetic results (OCR) balanced on both sides. Investigators are encouraged to use a variety of types and brands of dermal fillers, recruiting subjects for the study as necessary. Safety and performance evaluations will be made through a combination of clinical observations, questionnaires for the subject and for the Treating Investigator, and spontaneous reports of adverse events. There are 6 required study visits: Screening, Day 1 (Treatment Day), Day 3, Day 8, Day 15, and Day 29.

Description:

This is a randomized, evaluator-blind, bilateral, controlled, multicenter study. Subjects are to be recruited from the investigator's practice and randomized to receive treatment with the Artiste System on either the left or right nasolabial fold, the contralateral fold to be treated with standard manual injections. Treatments will occur in a single session to achieve optimal cosmetic results (OCR) balanced on both sides. There are no specific requirements with respect to the type or brand of dermal filler to be used, but the investigators will be encouraged to use a variety of types and brands in the context of the study, recruiting subjects for the study as necessary. Safety and performance evaluations will be made through a combination of clinical observations (by a Blinded Evaluator distinct from the Treating Investigator), questionnaires for the subject and for the Treating Investigator, and spontaneous reports of adverse events. There will be a total of 6 required study visits: Screening, Day 1 (Treatment Day), Day 3, Day 8, Day 15, and Day 29.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 50
• Est. completion date: February 2012
• Est. primary completion date: February 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female, at least 18 years of age;

• Presenting at Screening with bilateral nasolabial folds rated 2 or greater on the Wrinkle Severity Rating Scale (SRS) by the Blinded Evaluator.

• Willing and able to provide informed consent;

• In good health, based upon the subject's report and medical history.

Exclusion Criteria:

• History of keloids, bleeding disorders, or severe allergic or anaphylactic reactions, including hypersensitivity to any components of the study materials;

• Active inflammatory process, scarring, or dense facial hair in the area of the nasolabial folds;

• Any chronic or acute medical condition that, in the opinion of the investigator, may interfere with evaluation of the study results or place the subject at undue risk;

• History of previous cosmetic treatment of the nasolabial folds within 6 months prior to the Screening visit;

• Planning to undergo facial surgery during the 4-week course of the study;

• Participation in a clinical investigation within the 30 days prior to the Screening visit.

Related Conditions & MeSH terms

• Correction of Nasolabial Folds

Intervention

Procedure:
• Subdermal Injection
Injection of dermal filler

Device:
• Artiste Assisted Injection System
The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.

Locations

Country	Name	City	State
United States	Suzanne Bruce & Associates	Houston	Texas
United States	Z. Paul Lorenc	New York	New York
United States	Premier Clinical Research	Spokane	Washington

Sponsors (2)

Lead Sponsor	Collaborator
TKL Research, Inc.	Nordson Micromedics

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Injection Site Reactions	Severity ratings.	4 weeks
Primary	Patient Acceptability	Questionnaire	4 weeks
Primary	Investigator Acceptability	Questionnaire	4 weeks